<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://www.onhealthcare.tech/p/the-medicare-transaction-facilitator</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-26T13:11:50+00:00</news:publication_date><news:title>The Medicare Transaction Facilitator Turns a Negotiated Drug Price Into an Auditable Claim-Level Event: Two MTF Modules, a Seven-Day PDE Feed, the Part B NDC Identity Gap, and a 14-Day Event Clock</news:title></news:news></url><url><loc>https://www.onhealthcare.tech/p/part-ii-the-medicare-transaction</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-26T13:05:25+00:00</news:publication_date><news:title>Part II: The Medicare Transaction Facilitator Turns a Negotiated Drug Price Into an Auditable Claim-Level Event: Two MTF Modules, a Seven-Day PDE Feed and the Part B NDC Identity Gap</news:title></news:news></url><url><loc>https://www.onhealthcare.tech/p/part-i-the-medicare-transaction-facilitator</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-26T13:04:15+00:00</news:publication_date><news:title>Part I: The Medicare Transaction Facilitator Turns a Negotiated Drug Price Into an Auditable Claim-Level Event: Two MTF Modules, a Seven-Day PDE Feed and the Part B NDC Identity Gap</news:title></news:news></url><url><loc>https://www.onhealthcare.tech/p/how-a-split-fda-advisory-panel-voted-8b8</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-26T02:54:13+00:00</news:publication_date><news:title>How a Split FDA Advisory Panel Voted Six of Seven Peptides Onto the 503A Compounding List Over Its Own Scientists, Rejecting Only Emideltide, and What That Actually Changes for the Market</news:title></news:news></url><url><loc>https://www.onhealthcare.tech/p/how-a-split-fda-advisory-panel-voted</loc><news:news><news:publication><news:name>Thoughts on Healthcare Markets &amp; Technology</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-26T02:48:44+00:00</news:publication_date><news:title>How a Split FDA Advisory Panel Voted Six of Seven Peptides Onto the 503A Compounding List Over Its Own Scientists, Rejecting Only Emideltide, and What That Actually Changes for the Market</news:title></news:news></url></urlset>